Sanofi
在场
是其中之一......
- CAC 40;
- CAC All-Trade;
- Forbes Global 2000 (#122);
- Fortune 500 Europe (#74);
- Global Fortune 500 (#297);
- SBF 120;
- Stoxx 600;
- TOB Iconic 10,000.
Sanofi 是一家在股票代码 SAN (FR) 下上市的公司。
Sanofi 在 32 个国家有直接业务。Sanofi 拥有 45家子公司，其中包括 Amunix、Euroapi 和 Genzyme Denmark。
他们在：
涉及Sanofi的并购和融资。
- Sanofi has announced the acquisition of InhibRx (公布2024一月24号).
- Sanofi has announced the acquisition of Provention Bio (公布2023三月15号).
高管
查看带有其 353 名主要高管的组织结构图
Sanofi 搜索最多的简介
高管在Sanofi变化
- Audrey Derveloy 曾任 Chief Executive Officer, France, 将于 20247月1 升职为 Executive Vice President, Global Head of Corporate Affairs (新闻发布的2024六月23号).
- Frank Nestle, Chief Scientific Officer and Global Head of Research 请很快离开公司 (新闻发布的2024五月9号).
- John SundyJohn Sundy 将于20244月30作为 Independent Director 加入公司 (新闻发布的2024二月25号).
创建提醒
跟踪 Sanofi 的高管变动
药店
Sanofi 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Roche (瑞士)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Sanofi 的最新新闻稿
- Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
- Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
- Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
- Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
- Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
- Press Release: Sanofi in discussions to sell a controlling stake in Opella
- Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
- Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
- Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases
- Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
- View more press releases Close
通过电子邮件
